Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EBT (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of EBT readings, the most recent being $9.8 million for Q4 2025.

  • Quarterly EBT rose 200.14% to $9.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.3 million through Dec 2025, up 573.14% year-over-year, with the annual reading at $75.3 million for FY2025, 573.14% up from the prior year.
  • EBT hit $9.8 million in Q4 2025 for Oramed Pharmaceuticals, down from $59.5 million in the prior quarter.
  • Across five years, EBT topped out at $59.5 million in Q3 2025 and bottomed at -$23.0 million in Q3 2021.
  • Average EBT over 5 years is -$127705.9, with a median of -$5.2 million recorded in 2023.
  • The largest annual shift saw EBT surged 925.44% in 2024 before it tumbled 560.1% in 2025.
  • Oramed Pharmaceuticals' EBT stood at -$23.0 million in 2021, then surged by 46.69% to -$12.3 million in 2022, then soared by 208.49% to $13.3 million in 2023, then plummeted by 173.58% to -$9.8 million in 2024, then soared by 200.14% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBT are $9.8 million (Q4 2025), $59.5 million (Q3 2025), and $13.1 million (Q2 2025).